Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Long Acting Ophthalmic Analgesic Eye Drops

Posted Jun 15 2010 5:00pm

Description of Invention:
This invention is directed to the discovery that resiniferatoxin (RTX) produces a three to four day analgesic effect when topically applied to the cornea. Efficacy for RTX as an effective analgesic has been demonstrated in vivo in rats. Importantly, unlike currently available analgesics, RTX left the blink reflex intact and did not impact mechanical sensitivity. RTX also did not impair epithelial wound healing and functioned without detectable damage to the cornea.

RTX is a potent agonist of the transient receptor potential channel, subfamily V, member 1 (TRPV1). TRPV1 is involved in pain sensation and is expressed only in select neurons. Unlike other local analgesics that target a wide breadth of neurons, RTX targets only those neurons that express TRPV1, leaving the important blink reflex and mechanical sensitivity of the eye unaffected.

Applications:
  • An ophthalmic analgesic for post-operative eye pain
  • An ophthalmic analgesic for acute or chronic eye injury
  • Applicable to both human and veterinary patients


Advantages:
  • Both long lasting and reversible
  • Does not impair epithelial wound healing, leaves the blink reflex intact, and functions without detectable damage to the cornea


Development Status:
  • Early stage
  • Demonstrated efficacy in vivo in rats


Inventors:
Michael J Iadarola (NIDCR)
Andrew J Mannes (NIDCR)
Jason M Keller (NIDCR)
Kendall Mitchell (NIDCR)
Brian D Bates (NIDCR)


Patent Status:
HHS, Reference No. E-117-2009/0
US, Application No. 61/247,881 filed 01 Oct 2009


Relevant Publication:
  1. In preparation


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Institute of Dental and Craniofacial Research, Laboratory of Sensory Biology, Neurobiology and Pain Therapeutics Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact David W. Bradley, Ph.D. at 301-402-0540 or bradleyda@nidcr.nih.gov for more information.


Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
Ophthalmology
Ophthalmology - Therapeutics
In-vivo Data



For Additional Information Please Contact:
Norbert Pontzer Ph.D., J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 23,
Rockville, MD 20852
United States
Email: pontzern@mail.nih.gov
Phone: 301-435-5502
Fax: 301-402-0220


Ref No: 2089

Updated: 06/2010

Post a comment
Write a comment:

Related Searches